Patient Experience Survey
PhRMA’s Patient Experience Survey (PES) is a research initiative designed to explore the barriers patients face in accessing health care and prescription medicines. For example, 87% of Americans agree that if they got sick with a serious medical condition or disease, they would want to be treated in the United States. Findings from the robust quantitative survey, conducted in partnership with Ipsos, informs analysis that connects Americans’ real experiences to a policy agenda that addresses their needs and concerns.
Americans overwhelmingly value U.S. pharmaceutical leadership. But health insurance coverage costs and insurance-related barriers to care are problems to solve. Ultimately, from the lab to the pharmacy counter, insured Americans want a system that works for them.
Many insured Americans have faced insurance barriers to care in the past year – with this being an even bigger issue for chronic disease patients who are most in need of reliable access to care. Roughly half can’t anticipate what they’ll pay for Rx and have had trouble understanding their health insurance coverage. There is widespread support for cracking down on practices by insurance companies and PBMs and that can limit patient access to medicines.
PES Wave 4 - Protecting Lifelines to Access and Innovation, Summer 2023
Insured Americans overwhelmingly say they believe that insurance should provide affordable access to health care (93%), yet only a third (34%) say they believe it currently delivers. This survey shows how insured Americans face the repercussions of insurer and PBM practices, including unaffordable out-of-pocket costs, access barriers and risks to future innovative treatments.
Americans are struggling to navigate barriers imposed by insurance companies and pharmacy PBMs, including both utilization management restrictions like prior authorization and administrative burdens such as paperwork and time on the phone navigating coverage.
Many insurance practices exacerbate access and affordability issues. Americans vulnerable to these practices bear the impact of these insurer-imposed barriers on Americans’ livelihoods, adherence to medicines and access to care.
PES Wave 1 - Barriers to Health Care Access in the Patient Experience, Fall 2021
PhRMA’s Patient Experience Survey is a research initiative designed to explore the barriers patients face in accessing health care and prescription medicines. The research aims to understand how patients engage with the health care system, uncover the real, practical challenges Americans face around access and affordability and identify solutions that could make a meaningful difference.
Related resources
Americans believe U.S. pharma leadership needs to be protected
Americans have long benefited from America’s leadership in developing new medicines, spurring innovation and jobs and protecting the nation’s economic security. New data shows that Americans overwhelmingly value U.S. pharmaceutical leadership and acknowledge the stakes of falling behind are high.
As the latest Patient Experience Survey from PhRMA/Ipsos shows, Americans want policymakers to prioritize policies that continue to protect American innovation, strengthen research and manufacturing at home, and ensure patients continue to benefit from early access to lifesaving treatments.
Americans value medical innovation and want it to stay in the United States. For most Americans, the importance of U.S. leadership in medical innovation is both practical and personal. Nearly eight in 10 Americans (79%) say it is important that the United States is the global leader in developing new medicines. Large majorities say U.S. leadership is important for:
- Developing new medicines (90%)
- Giving Americans early access to new treatments (86%)
- Manufacturing medicines in the United States (83%)
- Competing globally in pharmaceutical innovation (82%)
- Ensuring American patients can participate in the newest clinical trials (83%)
This leadership matters and resonates deeply with Americans when they think about their own health. Nearly nine in 10 Americans (87%) agree that if they became seriously ill, they would want to be treated in the United States. This reflects a broad understanding of the pharmaceutical industry and its ability to deliver tangible benefits to patients and the country as a whole. Americans recognize these strengths and agree that:
- We should invest in pharmaceutical R&D and manufacturing because it creates good jobs (86%)
- Maintaining pharmaceutical leadership protects the United States from dependence on other countries for medicines (82%)
- Agree medical innovation is strategically important to our national security (76%)
Americans express worry about the consequences if the country loses ground on medical innovation. U.S. leadership in medical innovation is critical. If the United States were to lose ground, Americans see the following consequences as likely outcomes:
- Slower access to new medicines for patients (78%)
- Becoming dependent on foreign countries for medicines (77%)
- Losing the ability to participate in cutting-edge clinical trials (74%)
- Weaker responses to pandemics and public health emergencies (74%)
- Fewer new treatments for serious diseases (74%)
- Loss of high-paying jobs (71%)
The message is clear: Protect American innovation in medicine research, development and manufacturing. Americans understand how pharmaceutical innovation delivers lifesaving treatments, economic growth and global competitiveness. Protecting innovation isn’t just about science; it’s about safeguarding America’s health, prosperity and preparedness for the future.
Read the full Patient Experience Survey and learn more about how America Cures.
Mark Allen
PhRMA Launches Campaign Highlighting the Importance of America’s Global Leadership in Medicine Development
PhRMA also launches AmericasMedicines.com at annual PhRMA Forum
WASHINGTON, D.C. (February 17, 2026) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched America Cures, a new campaign underscoring why U.S. leadership in biopharmaceutical innovation matters now more than ever. The campaign highlights how our leadership in medicine development supports the fastest access to breakthrough treatments in the world, millions of high-paying American jobs and stronger national security.
“Global competition is intensifying. The launch of America Cures makes clear what’s at stake at this defining moment for U.S. leadership in medicine—and why it matters for American patients, jobs and our national security,” said Stephen J. Ubl, President and CEO of PhRMA. “America’s leading edge didn't happen by accident. It was built by smart, bipartisan policy choices and decades of sustained investment.”
New survey research from Ipsos underscores why our leadership in medicine matters to every American:
- 90% of Americans say it is important for the U.S. to be successful in developing new medicines.
- 87% of Americans agree that if they got sick with a serious medical condition or disease, they would want to be treated in the United States.
- 86% of Americans agree the U.S. should invest in pharmaceutical R&D and manufacturing because it creates good jobs.
- 63% of Americans support modernizing the FDA and drug development.
The campaign launched ahead of today’s PhRMA Forum 2026: Strengthening American Leadership, a half-day event focused on the policies needed to ensure the United States remains the world’s leader in developing and delivering innovative medicines to patients. The forum will feature discussions with top thought leaders including global biopharmaceutical CEOs, leading voices in health care disruption and AI as well as senior Trump Administration officials.
“At PhRMA Forum, leaders from government, industry and the patient community will focus on what it will take to protect that leadership and ensure the United States continues to develop cures for the world’s toughest diseases,” Ubl continued.
Today, PhRMA also launched AmericasMedicines.com, a new search tool that expands access to lower-cost medicines available through manufacturer direct purchase and patient support programs, simplifying the health care experience. Direct purchase and patient assistance programs help Americans afford innovative medicines, even as middlemen inflate costs and restrict access. According to Ipsos, nearly four in five (77%) insured Americans are interested in purchasing medicines from these platforms.
To read more about PhRMA’s campaign for strengthening American leadership, please visit www.AmericaCures.com.
For more information about PhRMA Forum 2026, click here.
PBMs/Insurance
Press Release
Fact Sheet - Patient Experience Survey Protecting Lifelines to Access and Innovation
Protecting Lifelines to Access and Innovation
There are repercussions of insurer- and PBM-imposed practices that drive up health care costs, put up barriers that stand between patients and their medicines and jeopardize access to innovation.
Fact Sheet
Fact Sheet - Patient Experience Survey: Navigating the Patient Experience: The Barriers and Burdens Standing Between Patients an
Navigating the Patient Experience: The Barriers and Burdens Standing Between Patients and Care
Insured Americans navigate unclear and unaffordable insurance coverage and the disproportionate impact such coverage has on more vulnerable communities.
Fact Sheet
Fact Sheet - Patient Experience Survey: Barriers to Health Care Access in the Patient Experience
Barriers to Health Care Access in the Patient Experience
COVID-19 exposed vulnerabilities of our health care system. This fact sheet helps us understand how patients engage with the health care system, uncover the real, practical challenges Americans face around access and affordability and identify solutions that would make a meaningful difference.
Fact Sheet